{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06092034",
            "orgStudyIdInfo": {
                "id": "RP-A501-0123"
            },
            "organization": {
                "fullName": "Rocket Pharmaceuticals Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease",
            "officialTitle": "Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-gene-therapy-study-of-rp-in-male-patients-with-danon-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-11",
            "studyFirstSubmitQcDate": "2023-10-17",
            "studyFirstPostDateStruct": {
                "date": "2023-10-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Rocket Pharmaceuticals Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.",
            "detailedDescription": "The study is a single arm Phase 2 clinical trial to characterize the safety and efficacy of RP-A501, a recombinant adeno-associated serotype 9 (rAAV9 capsid containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene) in male patients with Danon Disease.\n\nMale subjects \u22658 years of age will receive a single intravenous infusion of RP-A501."
        },
        "conditionsModule": {
            "conditions": [
                "Danon Disease"
            ],
            "keywords": [
                "Hypertrophic Cardiomyopathy",
                "HCM",
                "X-linked disease",
                "LAMP2",
                "Pediatric",
                "Skeletal Myopathies",
                "Cardiomyopathy",
                "Lysosomal Storage Disorder",
                "Left Ventricular Hypertrophy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "RP-A501",
                    "type": "EXPERIMENTAL",
                    "description": "One planned dose of RP-A501 in cohorts of subjects with a confirmed diagnosis of Danon Disease.",
                    "interventionNames": [
                        "Genetic: RP-A501"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "RP-A501",
                    "description": "RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.",
                    "armGroupLabels": [
                        "RP-A501"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluation of efficacy associated with RP-A501 via co-primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index",
                    "description": "Increase of myocardial tissue expression of LAMP2 protein and decrease in left ventricular mass index (LVMI).",
                    "timeFrame": "12 Months post-infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluation of efficacy associated with RP-A501 via components of the co-primary endpoint - LAMP2",
                    "description": "Increase in LAMP2 protein expression",
                    "timeFrame": "12 months post infusion"
                },
                {
                    "measure": "Evaluation of efficacy associated with RP-A501 via components of the co-primary endpoint - Left Ventricular Mass Index (LVMI)",
                    "description": "Decrease in Left Ventricular Mass Index (LVMI)",
                    "timeFrame": "12 months post infusion"
                },
                {
                    "measure": "Evaluation of efficacy associated with RP-A501 via biomarker evidence of myocardial injury - High Sensitivity Troponin I (hsTnI)",
                    "description": "Decrease in high sensitivity Troponin I (hsTnI)",
                    "timeFrame": "12 months post infusion"
                },
                {
                    "measure": "Evaluation of efficacy associated with RP-A501 via biomarker evidence of myocardial injury - N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)",
                    "description": "Decrease in N-terminal prohormone of brain natriuretic peptide (NT-proBNP)",
                    "timeFrame": "12 months post infusion"
                },
                {
                    "measure": "Evaluation of efficacy associated with RP-A501 via assessment of event-free survival",
                    "description": "Event free survival with events defined as death, heart transplant, mechanical circulatory support (MCS) or heart failure hospitalization and incidence of death, heart transplant, MCS, or heart failure hospitalization from baseline to 60 months post RP-A501 infusion.",
                    "timeFrame": "60 months post infusion"
                },
                {
                    "measure": "Evaluation of safety associated with RP-A501",
                    "description": "Incidence, severity and duration of treatment emergent safety events.",
                    "timeFrame": "60 months post infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Documentation of a pathogenic or likely pathogenic variant of the LAMP2 gene.\n2. Male.\n3. Age \u22658 years.\n4. Evidence of left ventricular hypertrophy with preserved systolic function phenotype as defined by each of the following:\n\n   1. Abnormal thickening of Left ventricular wall,\n   2. Left ventricular ejection fraction (LVEF) \u2265 50%.\n5. New York Heart Association (NYHA) Class II to III.\n6. High sensitivity Troponin I (hsTnI) \u226520% above the upper limit of normal (ULN)\n7. Ability to comply with study procedures including investigational therapy and follow-up evaluations.\n\nKey Exclusion Criteria:\n\n1. Anti-AAV9 neutralizing antibody titer \\>1:40.\n2. Severe heart failure or requirement for advanced therapies.\n3. History of intracardiac thrombosis or arterial thromboembolic events including stroke, transient ischemic attack (TIA), acute coronary syndrome, myocardial infarction or unstable angina.\n4. Prior cardiac or other organ (lung, liver, other) transplantation.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "8 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Information",
                    "role": "CONTACT",
                    "phone": "646-627-0033",
                    "email": "clinicaltrials@rocketpharma.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Joseph Rossano, MD",
                    "affiliation": "Children's Hospital of Philadelphia",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Barry Greenberg, MD",
                    "affiliation": "University of California San Diego (UCSD)",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Diego",
                    "status": "RECRUITING",
                    "city": "La Jolla",
                    "state": "California",
                    "zip": "92037",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Barry Greenberg, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.84727,
                        "lon": -117.2742
                    }
                },
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Rossano, MD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "German Heart Center Munich",
                    "status": "RECRUITING",
                    "city": "Munich",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "Cordula Wolf, MD",
                            "role": "CONTACT",
                            "email": "wolf@dhm.mhn.de"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.13743,
                        "lon": 11.57549
                    }
                },
                {
                    "facility": "Great Ormund Street Hospital & UCL Institute of Cardiovascular Science",
                    "status": "NOT_YET_RECRUITING",
                    "city": "London",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Juan Kaski, MD",
                            "role": "CONTACT",
                            "email": "j.kaski@ucl.ac.uk"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000052120",
                    "term": "Glycogen Storage Disease Type IIb"
                }
            ],
            "ancestors": [
                {
                    "id": "D000038901",
                    "term": "Mental Retardation, X-Linked"
                },
                {
                    "id": "D000008607",
                    "term": "Intellectual Disability"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009202",
                    "term": "Cardiomyopathies"
                },
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000006008",
                    "term": "Glycogen Storage Disease"
                },
                {
                    "id": "D000002239",
                    "term": "Carbohydrate Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008661",
                    "term": "Metabolism, Inborn Errors"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12154",
                    "name": "Cardiomyopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10035",
                    "name": "Hypertrophy",
                    "relevance": "LOW"
                },
                {
                    "id": "M5568",
                    "name": "Cardiomyopathy, Hypertrophic",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M26970",
                    "name": "Glycogen Storage Disease Type IIb",
                    "asFound": "Danon Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19658",
                    "name": "Hypertrophy, Left Ventricular",
                    "relevance": "LOW"
                },
                {
                    "id": "M18871",
                    "name": "Lysosomal Storage Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9114",
                    "name": "Glycogen Storage Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M11589",
                    "name": "Intellectual Disability",
                    "relevance": "LOW"
                },
                {
                    "id": "M24774",
                    "name": "Mental Retardation, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M11641",
                    "name": "Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M5498",
                    "name": "Carbohydrate Metabolism, Inborn Errors",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1740",
                    "name": "Danon Disease",
                    "asFound": "Danon Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}